“Expected Spesolimab Plasma Exposure Following Intravenous and Subcutaneous Dosing in Patients With Generalized Pustular Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s359, https://doi.org/10.25251/skin.8.supp.359.